To further compare CD155 and CD19 as tumor antigen targets, we examined the killing activity of both CAR-T cell types against NALM6 cells, a human B-cell leukemia line that co-expresses CD19 and CD155 (44), which was confirmed by using flow cytometry (Supplemental Figure 5H). Here, PVR is linked to neoplasm.